Article
Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure.
AIDS research and human retroviruses - 1 Jun 2003
González de Requena Daniel, Gallego Oscar, de Mendoza Carmen, Corral Angélica, Jiménez-Nácher Inmaculada, Soriano Vincent
Abstract excerpt
Virological failure under protease inhibitor (PI)-based antiretroviral regimens is often not explained by the selection of resistance mutations. The role of low indinavir (IDV) plasma levels in treatment failure was assessed in 46 subjects experiencing early virological failure to a first-line IDV-containing triple combination. Overall, 69% of patients showed subtherapeutic IDV plasma levels (it was not detected...
Topics
- Anti-HIV Agents
- Drug Resistance, Viral
- Drug Therapy, Combination
- HIV Infections
- HIV Protease
- HIV Protease Inhibitors
- HIV Reverse Transcriptase
- HIV-1
- Humans
- Indinavir
- Mutation
- Reverse Transcriptase Inhibitors
- Treatment Failure